Product Details

Global clinical trials: Calling the hype to task

The results of two recent studies suggest that the dispersion of clinical trials is not nearly as global as commonly believed. The promise of conducting clinical trials in emerging regions, gaining access to well-trained investigators and a large volume of treatment-naïve patients, and the realization of economic and efficiency advantages has been hyped. Clinical trials regulated by the FDA remain predominantly in mature global markets.

Advisory boards amplify patients’ voices

A strong and growing desire to solicit feedback directly from patients, experienced participants and their support network is prompting many sponsors and CROs to assess, plan and implement patient advisory panels.

Also in this issue:

• Building a better team with a lessons learned process
• Destruction of competition would counteract procurement’s aim
• Regulatory Update
• Month in Review
• FDA Actions
• Study Lead Opportunities
• New Drugs in the Pipeline